Regulatory T cell in stroke: A new paradigm for immune regulation

37Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Stroke is a common, debilitating trauma that has an incompletely elucidated pathophysiology and lacks an effective therapy. FoxP3+CD25 +CD4+ regulatory T cells (Tregs) suppress a variety of normal physiological and pathological immune responses via several pathways, such as inhibitory cytokine secretion, direct cytolysis induction, and antigen-presenting cell functional modulation. FoxP3+CD25 +CD4+ Tregs are involved in a variety of central nervous system diseases and injuries, including axonal injury, neurodegenerative diseases, and stroke. Specifically, FoxP3+CD25+CD4 + Tregs exert neuroprotective effects in acute experimental stroke models. These beneficial effects, however, are difficult to elucidate. In this review, we summarized evidence of FoxP3+CD25+CD4 + Tregs as potentially important immunomodulators in stroke pathogenesis and highlight further investigations for possible immunotherapeutic strategies by modulating the quantity and/or functional effects of FoxP3 +CD25+CD4+ Tregs in stroke patients. © 2013 Sheng Chen et al.

Cite

CITATION STYLE

APA

Chen, S., Wu, H., Klebe, D., Hong, Y., Zhang, J., & Tang, J. (2013). Regulatory T cell in stroke: A new paradigm for immune regulation. Clinical and Developmental Immunology. https://doi.org/10.1155/2013/689827

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free